Skip to content
value.today

Embecta Corp.: financial analysis

Ratios worked out from 6 fiscal years of Embecta Corp.'s statements, compared with 1,209 companies in Healthcare.

Operating margin, 2025
22.4%
Healthcare: -7.7%
Revenue growth, 3 years a year, 2025
-1.5%
Healthcare: 8.5%
Free cash flow margin, 2025
16.9%
Healthcare: -1.3%
Dividend yield, 2025
9.6%
Healthcare: 1.0%

Embecta Corp. scorecard#

Passes 16 of the 26 checks that could be worked out: strongest in shareholder returns (5 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation4 of 6
    • ✓P/E below its peers' median4.2×P/E 4.2× against Healthcare's median of 30.0×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Healthcare's median of 3.8×.
    • ✓Free cash flow yield above 5%49.8%Free cash flow is 49.8% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield23.9%Earnings yield 23.9% against the 10-year Treasury's 5.15% on 2026-11-13.
    • ✗The price assumes slower growth than the last three years'7.3%The price assumes 7.3% a year for ten years; revenue grew -1.5% a year over the last three.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-3.8%Revenue down 3.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-1.5%-1.5% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-1.5%-1.5% a year against Healthcare's median of 8.5% (549 companies).
    • ✓Earnings per share grew in the newest year1.62 vs 1.34Diluted EPS 1.62 in fiscal 2025 against 1.34 the year before (report's currency).
    • ✗Net income higher than five years earlier$95 M$95 M in fiscal 2025 against $428 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$95 MNet income $95 M in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median22.4%22.4% against Healthcare's median of -7.7% (674 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • ✓Return on invested capital above 10%31.1%31.1% in fiscal 2025.
    • ✗Operating margin wider than three years earlier22.4%22.4% in fiscal 2025 against 27.4% in 2022.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.41 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✗Net debt below three years of EBITDA4.2×Net debt 4.2 times EBITDA in fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.68Z-score 1.68 (distress zone) for fiscal 2025.
  • Shareholder returns5 of 5
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✓Dividends under 75% of net income36.7%Dividends were 36.7% of net income in fiscal 2025.
    • ✓Share count up no more than 2% in a year1.0%Diluted shares up 1.0% in fiscal 2025.
    • ✓Dividends and buybacks above 3% of the market value9.6%Dividends and buybacks were 9.6% of the market value.
    • ✓Free cash flow covers dividends and buybacks$182 MFree cash flow $182 M against $35 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Free cash flow has been positive 6 years in a row.

Worth a look

  • Revenue fell 3.8% against the year before.
  • Shareholders' equity is negative: -$651 million.
  • Net debt is 4.2 times a year's operating earnings before depreciation.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

6of 9
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseyes
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsno
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin roseno
  • Asset turnover roseyes

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

1.68Distress zone(below 1.81, where the formula's author found most of the failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.34× 1.20.41
Retained earnings to assets-0.41× 1.4-0.57
Operating income to assets0.22× 3.30.73
Market value to liabilities0.21× 0.60.13
Revenue to assets0.99× 10.99

Profitability#

Embecta Corp.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin62.6%65.5%66.9%68.6%68.7%58.4%57%
Operating margin22.4%14.9%19.8%27.4%42.2%-7.7%90%
Net margin8.8%7.0%6.3%19.8%35.6%-8.1%77%
Return on equity————71.1%-36.9%—
Return on assets8.0%6.3%6.1%23.9%52.6%-29.1%88%
Return on invested capital31.1%—35.9%55.6%69.4%11.2%89%

Growth#

Embecta Corp.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-3.8%0.2%-0.8%-3.1%7.4%10.2%19%
Revenue growth, 3 years a year-1.5%-1.2%1.1%——8.5%23%
Revenue growth, 5 years a year-0.1%————11.5%16%
Net income growth21.8%11.2%-68.5%-46.1%-3.0%12.0%62%
Earnings per share growth20.9%9.8%-68.6%-46.6%-2.9%8.2%63%

Financial strength#

Embecta Corp.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity————0.00×0.45×—
Net debt$1.2 B$1.3 B$1.3 B$1.3 B$0 M$7 M19%
Net debt to EBITDA4.15×6.44×4.99×3.71×0.00×1.78×20%
Current ratio2.41×2.03×2.12×2.21×1.78×3.18×40%
Equity share of assets-59.6%-57.4%-67.7%-82.1%75.4%56.0%8%

Cash#

Embecta Corp.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$182 M$20 M$41 M$389 M$420 M$-11 M86%
Free cash flow margin16.9%1.8%3.7%34.4%36.0%-1.3%84%
Cash conversion200.9%45.6%96.2%184.4%110.0%147.6%68%
Capital spending share of revenue0.9%1.4%2.4%2.1%3.2%2.3%—

Shareholder returns#

Embecta Corp.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Dividend yield9.6%————1.0%96%
Shareholder yield9.6%————2.3%88%
Dividend payout36.7%44.1%48.9%3.9%0.0%27.5%—
Change in share count1.0%1.0%0.5%0.8%0.0%9.4%74%

Efficiency#

Embecta Corp.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.91×0.90×0.97×1.21×1.48×0.53×78%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Dividend yield
Dividends paid in the fiscal year as a share of today's market value.
Shareholder yield
Dividends plus buybacks as a share of today's market value.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Embecta Corp.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 1,209 companies in Healthcare that Embecta Corp. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Embecta Corp.